SEC Form 4 · accession 0001140361-18-032160

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Jacob Van Naarden

Officer — Chief Business Officer

Period of report

Jul 9, 2018

Accepted (ET)

Jul 11, 2018 · 5:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001581720

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jul 9, 2018	M	1,541	$3.648	A	15,241	D
Common Stock^F2,F3	Jul 9, 2018	S	300	$185.3402	D	14,941	D
Common Stock^F2,F4	Jul 9, 2018	S	200	$186.19	D	14,741	D
Common Stock^F2,F5	Jul 9, 2018	S	641	$187.3749	D	14,100	D
Common Stock	Jul 9, 2018	S	200	$188.04	D	13,900	D
Common Stock	Jul 9, 2018	S	100	$189.12	D	13,800	D
Common Stock	Jul 9, 2018	S	100	$191.64	D	13,700	D
Common Stock	Jul 10, 2018	M	1,541	$3.648	A	15,241	D
Common Stock^F2,F6	Jul 10, 2018	S	680	$178.3943	D	14,561	D
Common Stock^F2,F7	Jul 10, 2018	S	361	$179.5006	D	14,200	D
Common Stock^F2,F8	Jul 10, 2018	S	300	$180.9467	D	13,900	D
Common Stock	Jul 10, 2018	S	100	$181.96	D	13,800	D
Common Stock	Jul 10, 2018	S	100	$183.19	D	13,700	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F9	$3.648	Jul 9, 2018	M	1,541	D	—	Jun 18, 2024	Common Stock	1,541	79,810	D
Employee Stock Option (right to buy)^F9	$3.648	Jul 10, 2018	M	1,541	D	—	Jun 18, 2024	Common Stock	1,541	78,269	D

Explanation of responses

F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2Represents the aggregate of sales effected on the same day at different prices.
F3Represents the weighted average sales price per share. The shares sold at prices ranging from $184.73 to $185.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4Represents the weighted average sales price per share. The shares sold at prices ranging from $185.75 to $186.63 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5Represents the weighted average sales price per share. The shares sold at prices ranging from $186.89 to $187.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6Represents the weighted average sales price per share. The shares sold at prices ranging from $177.91 to $178.74 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7Represents the weighted average sales price per share. The shares sold at prices ranging from $179.06 to $179.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8Represents the weighted average sales price per share. The shares sold at prices ranging from $180.54 to $181.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.